

# Failure at the Effector Phase: Immune Barriers at the Le Microenvironment

Clinical Cancer Research

13, 5256-5261

DOI: [10.1158/1078-0432.ccr-07-0892](https://doi.org/10.1158/1078-0432.ccr-07-0892)

Citation Report

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5250-5255.   | 3.2 | 57        |
| 2  | Toll-like Receptors in Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5280-5289.  | 3.2 | 114       |
| 3  | Immune Stimulatory Features of Classical Chemotherapy. , 2007, , 235-256.   |     | 3         |
| 4  | Transforming Growth Factor- $\beta$ 2 and the Immune Response: Implications for Anticancer Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 5262-5270.  | 3.2 | 417       |
| 5  | Age-dependent tolerance to an endogenous tumor-associated antigen. <i>Vaccine</i> , 2008, 26, 1863-1873.  | 1.7 | 34        |
| 6  | Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. <i>Vaccine</i> , 2008, 26, 5046-5057.                       | 1.7 | 227       |
| 7  | Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells. <i>Journal of Immunology</i> , 2008, 181, 3099-3107.   | 0.4 | 604       |
| 8  | Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. <i>Blood</i> , 2008, 112, 2817-2825.                                      | 0.6 | 35        |
| 9  | Dendritic Cells: A Critical Player in Cancer Therapy?. <i>Journal of Immunotherapy</i> , 2008, 31, 793-805.   | 1.2 | 71        |
| 10 | Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model. <i>Cancer Research</i> , 2009, 69, 4309-4318.  | 0.4 | 140       |
| 11 | Anergic T Cells Are Metabolically Anergic. <i>Journal of Immunology</i> , 2009, 183, 6095-6101.   | 0.4 | 243       |
| 12 | Central Role of Tumor-Associated CD8+ T Effector/Memory Cells in Restoring Systemic Antitumor Immunity. <i>Journal of Immunology</i> , 2009, 182, 4217-4225.  | 0.4 | 47        |
| 13 | Chapter 6 Oxidative Stress and Lymphocyte Persistence. <i>Advances in Cancer Research</i> , 2009, 102, 197-227.   | 1.9 | 22        |
| 14 | Enhancing Cancer Vaccine Efficacy via Modulation of the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2009, 15, 6476-6478.  | 3.2 | 16        |
| 15 | Combination approaches to immunotherapy: the radiotherapy example. <i>Immunotherapy</i> , 2009, 1, 1025-1037.   | 1.0 | 29        |
| 16 | Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers. <i>Clinical Cancer Research</i> , 2009, 15, 4277-4287.                        | 3.2 | 43        |
| 17 | Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. <i>European Journal of Immunology</i> , 2009, 39, 3121-3133. | 1.6 | 27        |
| 18 | Costimulatory and coinhibitory receptors in anti-tumor immunity. <i>Immunological Reviews</i> , 2009, 229, 126-144.   | 2.8 | 246       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity. <i>Immunity</i> , 2009, 31, 787-798.  | 6.6 | 679       |
| 20 | Immunotherapy for malignant melanoma â€“ Tracing Ariadneâ€™s thread through the labyrinth. <i>European Journal of Cancer</i> , 2009, 45, 2266-2273.  | 1.3 | 16        |
| 22 | Lamininâ€”21 produced by lymphatic endothelial cells induces chemotaxis for human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 601-610.   | 1.5 | 11        |
| 23 | Dendritic Cells. <i>Cancer Journal (Sudbury, Mass )</i> , 2010, 16, 318-324.   | 1.0 | 42        |
| 24 | Gene Signature in Melanoma Associated With Clinical Activity. <i>Cancer Journal (Sudbury, Mass )</i> , 2010, 16, 399-403.  | 1.0 | 232       |
| 25 | Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1655-1663.  | 2.0 | 57        |
| 26 | Tumor-Resident CD8+ T-cell: The Critical Catalyst in IL-12-Mediated Reversal of Tumor Immune Suppression. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 399-405.                                  | 1.0 | 14        |
| 27 | Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 753-763.                | 1.1 | 9         |
| 28 | Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 371-387.   | 1.7 | 69        |
| 29 | Cancer vaccines: Where are we going?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, S9-15.   | 0.7 | 7         |
| 30 | Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 5067-5078.                       | 3.2 | 212       |
| 31 | Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses. <i>Clinical Cancer Research</i> , 2010, 16, 5458-5468.                                  | 3.2 | 190       |
| 32 | Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-Aâ€“Specific, Tumor-Reactive CTL in Melanoma Patients. <i>Cancer Research</i> , 2010, 70, 7084-7092.                      | 0.4 | 57        |
| 33 | Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor Î¶ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 2769-2780.                             | 3.2 | 95        |
| 35 | Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization. <i>Journal of Immunology</i> , 2010, 185, 5082-5092. | 0.4 | 58        |
| 36 | Dendritic Cell Subsets as Vectors and Targets for Improved Cancer Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 173-192.  | 0.7 | 12        |
| 37 | Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 489-498.              | 1.9 | 236       |
| 38 | CCL2 Blockade Augments Cancer Immunotherapy. <i>Cancer Research</i> , 2010, 70, 109-118.   | 0.4 | 159       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 39 | Towards a Genetic Definition of Cancer-Associated Inflammation. American Journal of Pathology, 2010, 176, 2082-2087.   | 1.9 | 71        |
| 40 | Tolerance: an overview and perspectives. Nature Reviews Nephrology, 2010, 6, 569-576.  | 4.1 | 38        |
| 41 | Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. Expert Review of Molecular Diagnostics, 2010, 10, 897-919.   | 1.5 | 46        |
| 42 | Indoleamine 2,3-Dioxygenase Amino Acid Metabolism and Tumour-Associated Macrophages: Regulation in Cancer-Associated Inflammation and Immune Escape. , 2011, , 91-104.   |     | 0         |
| 44 | Pathway-Based Analysis of a Melanoma Genome-Wide Association Study: Analysis of Genes Related to Tumour-Immunsuppression. PLoS ONE, 2011, 6, e29451.   | 1.1 | 18        |
| 45 | CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. British Journal of Dermatology, 2011, 164, 720-728.   | 1.4 | 41        |
| 46 | Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy. Seminars in Oncology, 2011, 38, 236-242.  | 0.8 | 28        |
| 47 | Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models. Bulletin of Mathematical Biology, 2011, 73, 2-32.  | 0.9 | 330       |
| 48 | Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. International Journal of Cancer, 2011, 129, 2158-2170.                             | 2.3 | 127       |
| 49 | Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Current Opinion in Immunology, 2011, 23, 286-292.   | 2.4 | 134       |
| 50 | Induction of Antitumor Immune Responses with Recombinant Lentivector: Role of Skin Derived DCs. Current Cancer Therapy Reviews, 2011, 7, 261-266.  | 0.2 | 0         |
| 51 | Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice. Molecular Therapy, 2011, 19, 1727-1736.                                    | 3.7 | 40        |
| 52 | Recent Developments in Cancer Vaccines. Journal of Immunology, 2011, 186, 1325-1331.   | 0.4 | 168       |
| 53 | Lentivector Prime and Vaccinia Virus Vector Boost Generate High-Quality CD8 Memory T Cells and Prevent Autochthonous Mouse Melanoma. Journal of Immunology, 2011, 187, 1788-1796.                                | 0.4 | 16        |
| 54 | Nucleus Accumbens-Associated 1 Contributes to Cortactin Deacetylation and Augments the Migration of Melanoma Cells. Journal of Investigative Dermatology, 2011, 131, 1710-1719.                                  | 0.3 | 21        |
| 55 | Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research, 2012, 18, 5460-5470. | 3.2 | 86        |
| 56 | Galectin-1 in Melanoma Biology and Related Neo-Angiogenesis Processes. Journal of Investigative Dermatology, 2012, 132, 2245-2254.   | 0.3 | 64        |
| 57 | Nitric Oxide-Producing Myeloid-Derived Suppressor Cells Inhibit Vascular E-Selectin Expression in Human Squamous Cell Carcinomas. Journal of Investigative Dermatology, 2012, 132, 2642-2651.                    | 0.3 | 63        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 58 | Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1300-1310.  | 1.9  | 58        |
| 59 | Chemoimmunotherapy as long-term maintenance therapy for cancer. <i>Onc Immunology</i> , 2012, 1, 563-565.   | 2.1  | 13        |
| 60 | Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity. <i>International Journal of Oncology</i> , 2012, 41, 53-60.  | 1.4  | 9         |
| 61 | Enhanced MHC class I and costimulatory molecules on B16F10 cells by <i>Ganoderma lucidum</i> polysaccharides. <i>Journal of Drug Targeting</i> , 2012, 20, 582-592.   | 2.1  | 19        |
| 62 | Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma. <i>Cancer Research</i> , 2012, 72, 1070-1080.   | 0.4  | 461       |
| 63 | CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1833-1847.   | 2.0  | 43        |
| 64 | Innate immune sensing of cancer: clues from an identified role for type I IFNs. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1343-1347.  | 2.0  | 44        |
| 65 | Therapeutic Cancer Vaccines: Current Status and Moving Forward. <i>Journal of the National Cancer Institute</i> , 2012, 104, 599-613.   | 3.0  | 239       |
| 66 | T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGF $\beta$ 2) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. <i>Journal of Translational Medicine</i> , 2012, 10, 127. | 1.8  | 29        |
| 67 | Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 432-443.  | 2.0  | 28        |
| 68 | Cancer immunotherapy. <i>Molecular Oncology</i> , 2012, 6, 242-250.   | 2.1  | 71        |
| 69 | Influence of Genetic Variants in Type I Interferon Genes on Melanoma Survival and Therapy. <i>PLoS ONE</i> , 2012, 7, e50692.   | 1.1  | 16        |
| 70 | Cancer immunotherapy via dendritic cells. <i>Nature Reviews Cancer</i> , 2012, 12, 265-277.   | 12.8 | 1,738     |
| 71 | Recent Advances in Therapeutic Cancer Vaccines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 2-5.  | 0.7  | 11        |
| 72 | Vaccines for Melanoma and Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 263-275.  | 0.8  | 29        |
| 73 | The sweet and bitter sides of galectins in melanoma progression. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 592-601.   | 1.5  | 32        |
| 74 | Human dendritic cell subsets in vaccination. <i>Current Opinion in Immunology</i> , 2013, 25, 396-402.  | 2.4  | 53        |
| 75 | Dendritic-Cell-Based Therapeutic Cancer Vaccines. <i>Immunity</i> , 2013, 39, 38-48.  | 6.6  | 739       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 76 | Immune Stimulatory Features of Classical Chemotherapy. , 2013, , 395-414.  |     | 2         |
| 78 | Innate and adaptive immune cells in the tumor microenvironment. <i>Nature Immunology</i> , 2013, 14, 1014-1022.  | 7.0 | 3,109     |
| 79 | Strategies to reverse melanoma-induced T-cell dysfunction. <i>Clinics in Dermatology</i> , 2013, 31, 251-256.  | 0.8 | 8         |
| 80 | Prostate cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 253-262.  | 2.0 | 12        |
| 81 | Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2013, 25, 268-276.  | 2.4 | 352       |
| 82 | Tumor Microenvironment and Myeloid-Derived Suppressor Cells. <i>Cancer Microenvironment</i> , 2013, 6, 169-177.  | 3.1 | 112       |
| 83 | Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1879-1889.      | 0.3 | 92        |
| 84 | Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. <i>Expert Review of Vaccines</i> , 2013, 12, 285-295.   | 2.0 | 55        |
| 85 | Local Administration of TLR Ligands Rescues the Function of Tumor-Infiltrating CD8 T Cells and Enhances the Antitumor Effect of Lentivector Immunization. <i>Journal of Immunology</i> , 2013, 190, 5866-5873. | 0.4 | 24        |
| 86 | Uncovering the mechanisms that regulate tumor-induced T-cell anergy. <i>Oncolmmunology</i> , 2013, 2, e22679.  | 2.1 | 15        |
| 87 | Pathophysiological Characteristics of Melanoma In-Transit Metastasis in a Lymphedema Mouse Model. <i>Journal of Investigative Dermatology</i> , 2013, 133, 537-544.  | 0.3 | 13        |
| 88 | Examining T Cells at Vaccine Sites of Tumor-bearing Hosts Provides Insights to Dysfunctional T-Cell Immunity. <i>Journal of Immunotherapy</i> , 2013, 36, 41-51.   | 1.2 | 2         |
| 89 | <i>Ret</i> transgenic mouse model of spontaneous skin melanoma: focus on regulatory <scp>T</scp> cells. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 457-463.   | 1.5 | 9         |
| 90 | Therapeutic vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 219-221.   | 1.4 | 42        |
| 91 | Effects of conventional therapeutic interventions on the number and function of regulatory T cells. <i>Oncolmmunology</i> , 2013, 2, e27025.   | 2.1 | 148       |
| 92 | Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model. <i>Journal of Immunology</i> , 2013, 190, 2464-2471.  | 0.4 | 195       |
| 93 | Elimination of Metastatic Melanoma Using Gold Nanoshell-Enabled Photothermal Therapy and Adoptive T Cell Transfer. <i>PLoS ONE</i> , 2013, 8, e69073.  | 1.1 | 134       |
| 94 | PKC $\delta$ Regulates T Cell Motility via Ezrin-Radixin-Moesin Localization to the Uropod. <i>PLoS ONE</i> , 2013, 8, e78940.   | 1.1 | 14        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 95  | Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring. Current Proteomics, 2013, 10, 202-217.   | 0.1 | 30        |
| 96  | Gene Therapy for Melanoma: Progress and Perspectives. , 0, , .   |     | 1         |
| 97  | Immunological Tolerance. , 2014, , .   |     | 4         |
| 98  | Vaccines against Cancer. , 2014, , .   |     | 0         |
| 99  | Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients. American Journal of Ophthalmology, 2014, 158, 939-947.e5.  | 1.7 | 53        |
| 100 | Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor. Molecular Therapy, 2014, 22, 206-218.  | 3.7 | 65        |
| 102 | Implementing combinatorial immunotherapeutic regimens against cancer. OncoImmunology, 2014, 3, e27588.   | 2.1 | 13        |
| 103 | Targeted siRNA Silencing of Indoleamine 2, 3-Dioxygenase in Antigen-presenting Cells Using Mannose-conjugated Liposomes. Journal of Immunotherapy, 2014, 37, 123-134.                                | 1.2 | 33        |
| 104 | Cancer Immunotherapy via Dendritic Cells. , 2014, , 75-89.   |     | 11        |
| 105 | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival. Journal of Immunology Research, 2014, 2014, 1-10.  | 0.9 | 25        |
| 106 | Immunotherapy for solid tumorsâ€”a review for surgeons. Journal of Surgical Research, 2014, 187, 525-535.  | 0.8 | 16        |
| 107 | Myeloidâ€”derived suppressor cells in malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2014, 12, 1021-1027.  | 0.4 | 44        |
| 108 | Combining Targeted Therapy With Immunotherapy in <i>BRAF</i> -Mutant Melanoma: Promise and Challenges. Journal of Clinical Oncology, 2014, 32, 2248-2254.  | 0.8 | 184       |
| 109 | Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptorâ€”Transduced Human T cells in Solid Tumors. Clinical Cancer Research, 2014, 20, 4262-4273. | 3.2 | 339       |
| 111 | CEACAM1 Promotes Melanoma Cell Growth through Sox-2. Neoplasia, 2014, 16, 451-460.   | 2.3 | 29        |
| 112 | Introduction to the Role of the Immune System in Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 537-558.  | 0.9 | 8         |
| 113 | Myeloide Suppressorzellen (MDSC) beim malignen Melanom. JDDG - Journal of the German Society of Dermatology, 2014, 12, 1021-1027.  | 0.4 | 14        |
| 114 | Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell and Melanoma Research, 2015, 28, 490-500.   | 1.5 | 134       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 115 | Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+â€%HLA-DRlo/neg) found in aggressive pediatric sarcoma patients. , 2015, 3, 35.                                      |     | 45        |
| 116 | Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose cyclophosphamide in an orthotopic murine prostate cancer model. Wspolczesna Onkologia, 2015, 3, 187-194.      | 0.7 | 1         |
| 117 | Curcumin Analog DM-1 in Monotherapy or Combinatory Treatment with Dacarbazine as a Strategy to Inhibit In Vivo Melanoma Progression. PLoS ONE, 2015, 10, e0118702.   | 1.1 | 24        |
| 118 | The STING pathway and the T cell-inflamed tumor microenvironment. Trends in Immunology, 2015, 36, 250-256.   | 2.9 | 190       |
| 119 | The Next Hurdle in Cancer Immunotherapy: Overcoming the Nonâ€“T-Cellâ€“Inflamed Tumor Microenvironment. Seminars in Oncology, 2015, 42, 663-671.   | 0.8 | 388       |
| 120 | Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology, 2015, 4, e1026531.  | 2.1 | 26        |
| 121 | Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. , 2016, 166, 30-39.  |     | 102       |
| 122 | Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. OncoImmunology, 2016, 5, e1240857.                      | 2.1 | 56        |
| 123 | Protection against HPV-16â€“Associated Tumors Requires the Activation of CD8+ Effector Memory T Cells and the Control of Myeloid-Derived Suppressor Cells. Molecular Cancer Therapeutics, 2016, 15, 1920-1930. | 1.9 | 27        |
| 124 | Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunology Research, 2016, 4, 541-551.   | 1.6 | 153       |
| 125 | Regulation of the IL-10-driven macrophage phenotype under incoherent stimuli. Innate Immunity, 2016, 22, 647-657.  | 1.1 | 60        |
| 126 | IFN-Î» cancer immunotherapy: new kid on the block. Immunotherapy, 2016, 8, 877-888.  | 1.0 | 30        |
| 127 | Interplay Between Inflammation and Epigenetic Changes in Cancer. Progress in Molecular Biology and Translational Science, 2016, 144, 69-117.   | 0.9 | 39        |
| 128 | STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Reports, 2016, 15, 2357-2366.   | 2.9 | 134       |
| 129 | Mechanisms of immunological tolerance. Clinical Biochemistry, 2016, 49, 324-328.   | 0.8 | 19        |
| 130 | Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. Biotechnology Advances, 2016, 34, 565-577.  | 6.0 | 39        |
| 131 | Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses. Cancer Letters, 2016, 374, 175-185.  | 3.2 | 63        |
| 132 | Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. International Immunology, 2016, 28, 383-391.  | 1.8 | 223       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 133 | Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1057673.  | 2.1 | 67        |
| 134 | Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 327-339.                | 2.0 | 50        |
| 135 | CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. <i>Oncolmmunology</i> , 2016, 5, e1091554.  | 2.1 | 83        |
| 136 | Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. <i>Oncolmmunology</i> , 2017, 6, e1258503.  | 2.1 | 12        |
| 137 | The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. <i>Journal of Experimental Medicine</i> , 2017, 214, 381-400.  | 4.2 | 154       |
| 138 | A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. <i>Cancer Immunology Research</i> , 2017, 5, 468-479.  | 1.6 | 117       |
| 139 | Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4 <sup>+</sup> T cells combined with agonist $\pm$ -GITR mAb promotes durable CD8 <sup>+</sup> T-cell-dependent antitumor immunity. <i>Oncolmmunology</i> , 2017, 6, e1315487. | 2.1 | 12        |
| 140 | Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma—New Therapeutic Targets. <i>American Journal of Surgical Pathology</i> , 2017, 41, 998-1004.  | 2.1 | 40        |
| 141 | PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 740-746.   | 0.7 | 32        |
| 142 | Mechanisms of Resistance to Immune Checkpoint Antibodies. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 109-128.   | 0.9 | 26        |
| 143 | Immunotherapy of cancers comes of age. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1001-1015.  | 1.3 | 84        |
| 144 | The Tail and the String Sign: New Sonographic Features of Subcutaneous Melanoma Metastasis. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 370-374.   | 0.7 | 24        |
| 145 | Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .   | 0.8 | 9         |
| 146 | Adaptive Resistance to Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 213-227.   | 0.8 | 15        |
| 147 | Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 19-31.   | 0.8 | 212       |
| 148 | The Role of Tumor Microenvironment in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 51-64.  | 0.8 | 124       |
| 149 | Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses. <i>Viruses</i> , 2017, 9, 186.  | 1.5 | 61        |
| 150 | Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. <i>Oncotarget</i> , 2017, 8, 71249-71284.  | 0.8 | 138       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 151 | Bispecific antibody based therapeutics: Strengths and challenges. <i>Blood Reviews</i> , 2018, 32, 339-347.  | 2.8 | 120       |
| 152 | Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. <i>Case Reports in Oncology</i> , 2018, 10, 897-909.           | 0.3 | 57        |
| 153 | Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells. <i>Neoplasia</i> , 2018, 20, 401-409.                               | 2.3 | 11        |
| 154 | Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .  | 0.9 | 1         |
| 155 | Immunotherapies for the Treatment of Uveal Melanoma—History and Future. <i>Cancers</i> , 2019, 11, 1048.   | 1.7 | 56        |
| 156 | Molecular background of skin melanoma development and progression: therapeutic implications. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 129-138.                                    | 0.4 | 22        |
| 157 | An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 166-177. | 2.0 | 17        |
| 158 | Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780.           | 1.2 | 7         |
| 159 | Genetic instability as a driver for immune surveillance. , 2019, 7, 345.   |     | 9         |
| 160 | Real-world treatment patterns and clinical outcomes among patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e16328.   | 0.4 | 30        |
| 161 | Mathematical analysis of a tumour-immune interaction model: A moving boundary problem. <i>Mathematical Biosciences</i> , 2019, 308, 8-19.  | 0.9 | 5         |
| 162 | IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives. <i>Vaccines</i> , 2020, 8, 617.   | 2.1 | 14        |
| 163 | The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. <i>Nature Communications</i> , 2020, 11, 2749.   | 5.8 | 51        |
| 164 | The Effect of Exercise on Gene Expression and Signaling in Mouse Melanoma Tumors. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 1485-1494.                                    | 0.2 | 6         |
| 165 | Yap suppresses T-cell function and infiltration in the tumor microenvironment. <i>PLoS Biology</i> , 2020, 18, e3000591.   | 2.6 | 58        |
| 166 | The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma — an immunohistochemical study. <i>BMC Cancer</i> , 2021, 21, 641.                                 | 1.1 | 9         |
| 167 | Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. , 2021, 9, e002222.   |     | 24        |
| 168 | Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer. <i>Scientific Reports</i> , 2021, 11, 19154.                  | 1.6 | 17        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 169 | Antigen Specific Memory T Cells and Their Putative Need for the Generation of Sustained Anti-Tumor Responses. <i>Advances in Experimental Medicine and Biology</i> , 2010, 684, 155-165. | 0.8 | 4         |
| 170 | Transcriptional Profiling of Melanoma as a Potential Predictive Biomarker for Response to Immunotherapy. , 2011, , 229-238.  |     | 1         |
| 171 | Engineered Cell-Based Therapies: A Vanguard of Design-Driven Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2014, 844, 369-391.  | 0.8 | 4         |
| 172 | Cancer Immunotherapy: Overview in Brief. , 2013, , 549-565.  |     | 1         |
| 173 | The Immune System—A Hidden Treasure for Biomarker Discovery in Cutaneous Melanoma. <i>Advances in Clinical Chemistry</i> , 2012, 58, 89-140.   | 1.8 | 32        |
| 174 | Angiostasis as a way to improve immunotherapy. <i>Thrombosis and Haemostasis</i> , 2009, 101, 1025-1031.   | 1.8 | 15        |
| 175 | Th9 cells promote antitumor immune responses in vivo. <i>Journal of Clinical Investigation</i> , 2012, 122, 4160-4171.   | 3.9 | 303       |
| 176 | HIV-1 Adenoviral Vector Vaccines Expressing Multi-Trimeric BAFF and 4-1BBL Enhance T Cell Mediated Anti-Viral Immunity. <i>PLoS ONE</i> , 2014, 9, e90100.                               | 1.1 | 17        |
| 177 | A Biased Competition Theory of Cytotoxic T Lymphocyte Interaction with Tumor Nodules. <i>PLoS ONE</i> , 2015, 10, e0120053.  | 1.1 | 9         |
| 178 | Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. <i>Immunotherapy</i> , 2009, 1, 645-661.  | 1.0 | 57        |
| 179 | Agonists of Receptors of the Innate Immunity and Defective Viral Particles as New Generation of Adjuvants. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2018, 17, 76-86.               | 0.2 | 2         |
| 180 | Identification of lncRNA-mRNA Regulatory Module to Explore the Pathogenesis and Prognosis of Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 615671.             | 1.8 | 17        |
| 181 | Do Cancer Stem Cells have an Immunomodulatory Role Different from the Bulk of Tumor Cells?. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2013, S14, .                            | 0.3 | 5         |
| 182 | Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. <i>World Journal of Biological Chemistry</i> , 2011, 2, 193.  | 1.7 | 26        |
| 183 | Targeted Therapy for Melanoma. , 2011, , 613-622.  |     | 0         |
| 184 | Targeting the Proteasome in Melanoma. , 0, , .   |     | 0         |
| 185 | Predictive Biomarkers as a Guide to Future Therapy Selection in Melanoma. , 2012, , 27-40.   |     | 0         |
| 186 | STAT3 and Src Signaling in Melanoma. , 2012, , 89-105.   |     | 0         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 187 | Introduction to Cutaneous Melanoma. , 2013, , 1-12.  |      | 0         |
| 189 | Melanoma with regression and in-transit metastasis. <i>Medicine and Pharmacy Reports</i> , 2016, 89, 165-168.  | 0.2  | 0         |
| 193 | Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches. <i>Leukemia and Lymphoma</i> , 2021, , 1-10.   | 0.6  | 1         |
| 194 | Mechanisms of immune activation and regulation: lessons from melanoma. <i>Nature Reviews Cancer</i> , 2022, 22, 195-207.   | 12.8 | 101       |
| 195 | Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 864739.   | 2.2  | 40        |
| 199 | Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma: A Case Report. <i>Internal Medicine</i> , 2023, , .                       | 0.3  | 1         |
| 200 | Advancements in Cancer Immunotherapies. <i>Vaccines</i> , 2023, 11, 59.  | 2.1  | 8         |
| 201 | The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook. <i>Clinical and Translational Oncology</i> , 2023, 25, 1545-1553. | 1.2  | 3         |
| 202 | Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities. , 2023, 40, .   |      | 0         |
| 203 | A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy. <i>Biomaterials Science</i> , 2023, 11, 2200-2210.   | 2.6  | 6         |
| 204 | A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia. <i>Frontiers in Immunology</i> , 0, 14, .                                  | 2.2  | 5         |
| 206 | Immunotherapy for Ocular Tumors. , 2023, , 1-61.   |      | 0         |